Mevalonate pathway inhibitor as highly-efficient vaccine adjuvant

US11382971B2 · kind B2 · utility

Assignee

• TSINGHUA UNIVERSITY · CN

Inventors

• Yonghui Zhang · Old Saybrook, US
• Yun Xia · Beijing, CN
• Yonghua Xie · Beijing, CN
• Zhengsen Yu · Beijing, CN
• Xiaoying Zhou · Beijing, CN
• Xin Li · Foshan, CN
• Liping Li · Jinan, CN
• Yunyun Yang · 红钢城街道, CN
• Kanzhao Gao · Beijing, CN
• Ke Wang · New York, US
• Wanli Liu · Beijing, CN
• Meng Zhao · Beijing, CN

Key dates

• Filing date: Sep 8, 2016
• Grant date: Jul 12, 2022
• Expiry date: Sep 18, 2036

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Disclosed are inhibitors of mevalonate pathway as an efficient vaccine adjuvant and use thereof. In particular, the inhibitor is an acetoacetyl-CoA transferase inhibitor, a HMG-CoA synthase inhibitor, a HMG-CoA reductase inhibitor, a mevalonate kinase inhibitor, a phosphomevalonate kinase inhibitor, a mevalonate-5-pyrophosphate decarboxylase inhibitor, an isopentenyl pyrophosphate isomerase inhibitor, a farnesyl pyrophosphate synthase inhibitor, a geranylgeranyl pyrophosphate synthase inhibitor or a geranylgeranyl transferase (I, II) inhibitor. Also disclosed is an immunogenic composition comprising inhibitors of mevalonate pathway as an adjuvant.